ScoreWhy is Oncolys BioPharma, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate -221.96% of over the last 5 years
3
Flat results in Dec 25
- INTEREST(HY) At JPY 2.95 MM has Grown at 22.1%
- NET SALES(9M) At JPY 28.55 MM has Grown at -9.04%
- DEBTORS TURNOVER RATIO(HY) Lowest at 0.11 times
4
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 226.70%, its profits have fallen by -8.1%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Oncolys BioPharma, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Oncolys BioPharma, Inc.
226.7%
2.74
90.49%
Japan Nikkei 225
36.73%
1.30
28.24%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-52.70%
EBIT Growth (5y)
-221.96%
EBIT to Interest (avg)
-349.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.39
EV to EBIT
-7.09
EV to EBITDA
-7.09
EV to Capital Employed
31.37
EV to Sales
471.78
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-442.33%
ROE (Latest)
-108.99%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
NET PROFIT(HY)
Higher at JPY -742.05 MM
ROCE(HY)
Highest at -60.96%
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -85.04 %
-11What is not working for the Company
INTEREST(HY)
At JPY 2.95 MM has Grown at 22.1%
NET SALES(9M)
At JPY 28.55 MM has Grown at -9.04%
DEBTORS TURNOVER RATIO(HY)
Lowest at 0.11 times
Here's what is working for Oncolys BioPharma, Inc.
Net Profit
Higher at JPY -742.05 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (JPY MM)
Debt-Equity Ratio
Lowest at -85.04 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Oncolys BioPharma, Inc.
Interest
At JPY 2.95 MM has Grown at 22.1%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Net Sales
At JPY 28.55 MM has Grown at -9.04%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (JPY MM)
Debtors Turnover Ratio
Lowest at 0.11 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
